ArticlePharmaceutical research2025
Development of Candesartan Cilexetil-sodium Carbonate Anhydrate-mesoporous Silica Solid Dispersion in Polymer-free System.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeCandesartan cilexetil (CDST) is used to treat hypertension; the drug belongs to the Biopharmaceutics Classification System (BCS class II) due to its low solubility in aqueous solutions. The commercial product, Atacand®Tab, contains 16 mg of CDST in a small tablet weighing approximately 130 mg. This study developed a polymer-free system by using a CDST solid dispersion (SD) of sodium carbonate anhydrate and mesoporous silica.
methodsThe SD formulation was developed to ensure solubilization and stability of CDST using a solvent evaporation method.
resultsThe dissolution (%) of CDST in the optimal formulation (SD1) at 60 min in pH1.2 medium, pH4.0 buffer, distilled water (DW), and pH6.8 buffer without polysorbate 20 increased by 35.2-, 45.5-, 34.4-, and 28.1-fold compared to that of Atacand®Tab and by 63.4-, 37.5-, 1.7-, and 46.9-fold, respectively, compared to the physical mixture (PM1). The dissolution of SD1 formulation was over 98% in DW and pH6.8 buffer after 60 min. The physicochemical properties of the SD1 formulation changed the melting point, drug-excipient interaction, and crystallinity of CDST. Additionally, the stability of SD1 formulation for 12 months was secured.
conclusionsThe SD1 formulation improved the dissolution of CDST and secured stability by changes in its physicochemical properties.
Indexed as
Identifiers
40721914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.